|
EC 2.7.11.26 (tau-protein kinase) inhibitor
|
CHEBI_91092 |
|
|
EC 2.7.11.* (protein-serine/threonine kinase) inhibitor
|
CHEBI_76812 |
|
|
disinfectant
|
CHEBI_48219 |
|
|
antimicrobial agent
|
CHEBI_33281 |
|
|
antiseptic drug
|
CHEBI_48218 |
|
|
antiinfective agent
|
CHEBI_35441 |
|
|
anti-obesity agent
|
CHEBI_74518 |
|
|
pharmacological role
|
CHEBI_52210 |
|
|
infratentorial cancer
|
DOID_4706 |
|
|
brain cancer
|
DOID_1319 |
|
|
foramen magnum meningioma
|
DOID_4708 |
|
|
meningioma
|
DOID_3565 |
|
|
skull base meningioma
|
DOID_4437 |
|
|
EC 1.1.1.44 (NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase) inhibitor
|
CHEBI_74520 |
|
|
EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor
|
CHEBI_76835 |
|
|
EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor
|
CHEBI_86501 |
|
|
EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor
|
CHEBI_76841 |
|
|
purinergic receptor P2X antagonist
|
CHEBI_91081 |
|
|
purinergic receptor P2 antagonist
|
CHEBI_91079 |
|
|
collagen cross-linking inhibitor
|
CHEBI_91085 |
|
